Clinical Trials Logo
  1. Home
  2. Atopic Asthma
  3. NCT03665701

Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites — 18-03 EONOV  

Atopic Asthma Clinical Trial

Official title:
Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites

Clinical Trial Summary

The aim of this study is to draw blood from patients with well-defined atopic asthma that will be subsequently used in invitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2. The inhibitory activity of a potent DP2 receptor antagonist, Fevipripant, shall be determined.

Clinical Trial Description

The inhibitory activity of a potent DP2 receptor antagonist shall be determined. For these experiments eosinophil granulocytes and ILC2 cells will be isolated from the collected blood samples and used in specific assays in respect to their functional reactivity against the DP2 receptor antagonist Fevipiprant after respective stimulation using Prostaglandin D2 metabolites or Prostaglandin D2. Major rationale is to show and determine the EC70 of the effectivity of Fevipiprant against Prostaglandin D2 metabolite triggered activation of eosinophil granulocytes and ILC2 innate lymphoid cells. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03665701
Study type Interventional
Source Fraunhofer-Institute of Toxicology and Experimental Medicine
Contact
Status Completed
Phase N/A
Start date August 16, 2018
Completion date December 16, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT01448954 - A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma Phase 2
Withdrawn NCT01049178 - Randomized Controlled Trial of Silymarin in Asthma Phase 2/Phase 3
Terminated NCT00644514 - Genetics of Asthma - Bronchoscopy Studies Phase 1
Completed NCT00861211 - Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects Phase 2
Completed NCT00784459 - The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics Phase 2
Terminated NCT00671593 - Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge Phase 1
Completed NCT05098600 - The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
Completed NCT01420003 - Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics N/A
Completed NCT02758548 - Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects Phase 2
Completed NCT01179256 - Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma N/A
Completed NCT01545245 - Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants N/A
Completed NCT03603522 - Probiotics and Capsaicin Evoked Coughs N/A
Completed NCT04728711 - A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC) Phase 2
Recruiting NCT03928431 - Restoration of Microbiota in Neonates N/A
Completed NCT02327234 - Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma N/A
Completed NCT01890161 - A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma Phase 2
Completed NCT04397081 - Atopic Diseases & Human Papilloma Virus